Skip to main content
Premium Trial:

Request an Annual Quote

InSilixa Awarded NIH Grant to Develop Point-of-Care Test for Drug-resistant Tuberculosis

NEW YORK (GenomeWeb) – InSilixa announced yesterday that it has received a $1.5 million Phase II Small Business Innovation Research grant from the National Institutes of Health to develop a point-of-care molecular diagnostic test for the rapid detection and profiling of antibiotic-resistant Mycobacterium tuberculosis.

The test will be based on InSilixa's proprietary complementary metal-oxide semiconductor (CMOS) biochip technology, which is designed to detect pathogens in clinical samples and simultaneously identify their drug-resistance profiles using highly multiplexed targeted DNA sequencing.

According to the company, the test will check hundreds of known tuberculosis mutations and perform a comprehensive multi-drug resistance test for up to five key antibiotics in less than an hour.

InSilixa is also developing the CMOS biochips for the detection of other multi-drug resistant bacteria and for the detection, quantification, and characterization of HIV in blood samples.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.